EBL sells telecom division to Sunrise
EBL has been active in the telecom business since 2000 and owns telecom networks in around 200 communities in Switzerland. At the same time, EBL has been successfully pursuing a strong expansion of its business with renewable...
Novaremed and NeuroFront enter option and license agreement for NRD.E1
Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications.
ImmunOs Therapeutics AG to raise CHF 74m Series B financing
ImmunOs Therapeutics AG has agreed to a CHF 74 million Series B financing led by incoming co-lead investors Samsara Biocapital, Lightspeed Venture Partners and Gimv, corner-stoned by GL Capital, Mission BioCapital, Peak 6 Strategic Capital and Fiscus Financial
Anaveon to raise CHF 110m in oversubscribed Series B financing
Anaveon AG ("Anaveon"), a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing.
msg systems ag acquired Optravis LLC
msg systems ag, an international IT consulting and system integration company based in Munich, has acquired Optravis LLC, based in Basel.
Novaremed acquires Metys Pharmaceuticals
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals.
Polyphor and EnBiotix sign merger agreement and sale of Murapavadin
Polyphor and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, have signed a merger agreement.
Sale of Mestex AG to Grünenthal
The previous owners of Mestex AG, a Swiss biotech company developing, sold their shares and stock options to the pharmaceutical company Grünenthal
Majority stake of STIMIT sold to Dräger
The Swiss-based start-up medical technology company STIMIT AG was founded in 2018...
Spaeter Pension Fund sells residential real estate portfolio to 1291 AST
The Spaeter Group's Pension Fund Foundation sells an attractive, highly profitable residential real estate portfolio with properties in four cantons of German-speaking Switzerland and with a total value of CHF 45.8m to 1291 Die Schweizer Anlagestiftung (AST) by means of a contribution in kind and transfer of assets in accordance with the Merger Act.